vTv Therapeutics Inc
vTv Therapeutics Inc (VTVT) is a small-cap biotech focused on developing orally delivered small-molecule therapies, historically centred on metabolic and neurological indications. As a clinical-stage company with a market capitalisation around $67 million, it typically has limited or no commercial revenue and is dependent on clinical trial progress, regulatory decisions and potential partnerships to create value. Investors should expect higher-than-average volatility: positive trial results or new licensing agreements can lift the stock, while setbacks, delays or financing needs can depress it. Key items to watch are trial readouts, regulatory updates, cash runway and any collaboration or licensing deals. Given its size, the company may need to raise capital periodically, which could dilute existing shareholders. This summary is for educational purposes only and not personal investment advice; investing in small biotechs carries material risk and investors may wish to seek independent financial advice.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying vTv Therapeutics stock, anticipating its price could rise significantly.
Financial Health
vTv Therapeutics Inc has modest revenue and cash flow, but its financial position needs improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring VTVT
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage catalysts
Trial readouts and regulatory milestones can create sharp share-price moves, though outcomes are uncertain and may disappoint.
Pipeline and focus
The company focuses on small-molecule therapies in metabolic and neurological areas, offering potential upside alongside typical clinical-stage risk.
Capital and partners
Watch cash runway and any licensing or partnership activity, since raising funds could dilute holders while deals can de‑risk programmes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
